

# UNC Molecular Pathology and Genetics Laboratory Test Menu

McLendon Clinical Laboratories, UNC Hospitals,  
101 Manning Drive, Chapel Hill NC 27514  
(984) 974-1825

<https://www.unccmedicalcenter.org/mclendon-clinical-laboratories/directory/molecular-pathology-and-genetics/>

Karen Weck MD [karen\\_weck@med.unc.edu](mailto:karen_weck@med.unc.edu); Margaret L. Gulley MD, [margaret\\_gulley@med.unc.edu](mailto:margaret_gulley@med.unc.edu); Leigh Thorne MD, [lthorne@med.unc.edu](mailto:lthorne@med.unc.edu); Jessica Booker PhD, [Jessica.Booker@unchealth.unc.edu](mailto:Jessica.Booker@unchealth.unc.edu); Lori Ramkissoon PhD, [Lori.Ramkissoon@unchealth.unc.edu](mailto:Lori.Ramkissoon@unchealth.unc.edu); Kelly Rafferty PhD [Kelly.Rafferty@unchealth.unc.edu](mailto:Kelly.Rafferty@unchealth.unc.edu); Rachana Kshatriya MS, M(ASCP), [Rachana.Kshatriya@unchealth.unc.edu](mailto:Rachana.Kshatriya@unchealth.unc.edu) Ryan O'Mara, CG(ASCP)<sup>CM</sup> [Ryan.Omara@unchealth.unc.edu](mailto:Ryan.Omara@unchealth.unc.edu)

---

## **Molecular Oncology Tests**

- ABL1 mutation** – Sequence the kinase domain of the *BCR-ABL1* fusion gene transcript to predict response to tyrosine kinase inhibitors in patients with leukemia
- BCR-ABL1 translocation** - Quantify p210 or p190 transcripts for diagnosis, monitoring and therapy selection in chronic myeloid leukemia and acute lymphoblastic leukemia
- BRAF mutation** – detect *BRAF* V600 codon activating mutation in carcinoma or melanoma tissue, or suspected hairy cell leukemia blood or marrow
- FLT3** - In acute myeloid leukemia, detect *FLT3* internal tandem duplication (ITD) or tyrosine kinase domain (TKD) mutation, impacting prognosis and response to targeted therapy
- Glioma panel** – In tumor tissue, test *TERT* promoter and *IDH1* and *IDH2* mutation to classify glioma
- JAK2** – quantify *JAK2* 1849G>T [V617F] in blood to detect or monitor myeloproliferative neoplasia
- IDH mutation** – Classify glioma by detecting *IDH1* R132 or *IDH2* R172 mutation
- Immunoglobulin and T cell receptor genes** - Detect rearrangement of the *IGH*, *IGK* and *TRG* genes to assess clonality and lineage of B and T cell lesions
- MGMT methylation** – Detect promoter methylation associated with sensitivity to alkylating agents in *IDH* wild type glioma tissue
- Microsatellite Instability** – In cancer tissue, assess defective mismatch repair, and inform response to immunotherapy and/or likelihood of Lynch syndrome.
- MLH1 methylation** – Test promoter methylation in the workup of possible Lynch syndrome and/or to inform response to immunotherapy
- Myeloid Mutation Panel** – In blood, marrow or tissue, detect hotspot mutations in multiple genes for diagnosis, prognosis and/or therapy selection in patients with acute myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasia
- Myeloproliferative Neoplasm Hotspot Panel** – In blood or marrow suspected of myeloproliferative neoplasia, detect mutation in *JAK2*, *CALR*, or *MPL* genes
- NPM1** – quantify *NPM1* type A mutation in blood to monitor leukemia burden
- Prosigna Breast Cancer Risk of Recurrence Score** – Assess prognosis in early-stage ER or PR positive, Her2 negative breast cancer with up to 3 involved nodes.
- T-cell Large Granular Lymphocytic Leukemia** - Testing for the presence of somatic mutations may assist in the diagnosis of T-cell large granular lymphocytic leukemia (T-LGLL). Mutations of *STAT3* and *STAT5B* can aid in distinction of reactive and neoplastic proliferations of T-cell large granular lymphocytes

## **Heritable and Congenital Disease Tests**

**Alpha-1-antitrypsin** - Detect *SERPINA1* mutation at E342K (Z allele) and E264V (S allele) associated with deficiency of the enzyme alpha-1-antitrypsin

**Apolipoprotein E (APOE)** – Detect *APOE* e2, e3, and e4 alleles for patients with Alzheimer disease being considered for treatment with monoclonal antibodies against aggregated beta amyloid such as Leqembi® (lecanemab-irmb) and to predict risk of late-onset Alzheimer.

**APOL1** - Detect *APOL1* G1 or G2 alleles associated with risk of kidney disease

**Connexin 26 and 30** – In blood or stored newborn blood card, detect *GJB2* (exon 2) mutation and *GJB6* deletions associated with altered connexin 26 and 30 proteins and congenital hearing loss

**CYP2C19** - Detect *CYP2C19* gene variants associated with drug efficacy or resistance to clopidogrel (Plavix) therapy

**Cystic fibrosis** - test for common mutations in the *CFTR* gene, offered to women of childbearing age and to patients with signs or symptoms of cystic fibrosis

**Factor V & Factor II** - Detect Factor V Leiden (*F5* c.1601G>A, p.R534Q) and prothrombin (*F2* 20210G>A) mutations associated with inherited predisposition to venous thrombosis

**Fragile X genotype** - Detect altered *FMR1* gene associated with Fragile X syndrome, premature ovarian failure, and tremor/ataxia syndrome

**Hemochromatosis** - Detect *HFE* mutation (63H>D & 282C>Y) associated with heritable predisposition to iron overload

**Kidney Genetics Mutation Panel** – Detect mutation in 17 genes associated with heritable forms of kidney disease, including nephrotic syndrome, focal segmental glomerulosclerosis (FSGS), and Alport syndrome

**Prader-Willi & Angelman Syndromes** - Detect methylated (maternal) and unmethylated (paternal) alleles of the *SNRPN* gene

**Primary Ciliary Dyskinesia** - Detect mutation in multiple genes associated with ciliary dysfunction in respiratory tracts or sperm motility (required history and consent forms)

**SMN1, SMN2** – Screen for potential carriers of spinal muscular atrophy or support diagnosis in an affected patient

**UGT1A1** – Assess promoter of the *UGT1A1* gene to predict toxicity to irinotecan or to confirm a diagnosis of Gilbert's syndrome

## **Additional Test Services**

**DNA Fingerprinting** - In allogeneic transplant patients, quantify proportions of recipient and donor cells in blood or marrow. In products of conception or prenatal specimens, estimate maternal and fetal fractions.

**Custom DNA sequencing** – Detect selected gene variants.

**DNA or RNA extract and hold** - extract DNA or RNA from specimen and hold for  $\geq 1$  year

**Validation of assays for use in clinical trials** – Genomic sequencing, PCR, expression profiles, & related technologies are developed to suit a given clinical investigation

**UNC Molecular Pathology and Genetics Laboratory Website** has a one-page information sheet about each test:

<https://www.unccmedicalcenter.org/mclendon-clinical-laboratories/directory/molecular-pathology-and-genetics/>